Discover investment opportunities in Stocks For Under 50 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks For Under 50 Cents using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Stocks For Under 50 Cents using our Smart AI Filter.
8 stocks found for "Stocks For Under 50 Cents"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.35 | ±93.0% | 2.3 | 0.00% | |||
1.07 | ±100.0% | -0.1 | 0.00% | |||
2.07 | ±100.0% | -4.2 | 0.00% | |||
0.45 | ±100.0% | -0.4 | 0.00% | |||
1.43 | ±75.7% | -0.7 | 0.00% | |||
1.24 | ±65.3% | 3.0 | 0.00% | |||
1.90 | ±100.0% | 1.1 | 0.00% | |||
0.51 | ±100.0% | -0.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What are the growth prospects for METX, a stock priced under 50 cents?
A: METX operates in the education technology sector and aims to expand its offerings in online learning and vocational training in China. Investors may see potential due to the growing demand for e-learning. However, it's essential to assess market penetration and financial health before investing.
Q: Is CEI a good choice for investors seeking exposure to the energy sector?
A: CEI, or Camber Energy Inc., focuses on oil and gas. It may appeal to those interested in energy resources, but its low stock price can signal volatility. Investors should consider the company's reserves, production capabilities, and regulatory environment.
Q: How does MULN compare to other automotive manufacturers?
A: MULN is part of the EV industry and aims to compete with established automakers. Its low price could reflect market skepticism. Potential investors should look into its production plans, capital requirements, and market positioning.
Q: Could SNDL be a viable option for investors interested in cannabis stocks?
A: SNDL operates in the cannabis industry and may attract those seeking growth in this sector. The company has experienced volatility due to regulatory changes and market competition. Analyzing its financials and strategic initiatives is recommended.
Q: What is the investment appeal of PSTV, especially in the biotech sector?
A: PSTV is involved in biotechnology, focusing on developing therapies for cancer and rare diseases. Its appeal lies in potential breakthroughs, but high research costs and regulatory hurdles can be significant risks.
Q: How is the technology company LKCO performing in emerging markets?
A: LKCO offers technology solutions primarily in China, including AI and Big Data. Some investors see potential due to increasing tech adoption, but geopolitical tensions and regulatory changes can impact its operations.
Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreDragonfly Energy Holdings Corp. (DFLI) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to a loss of $1.98 per share a year ago.
Read moreWe are initiating coverage of Adaptimmune Therapeutics plc ADAP with a 12-month price target of $3.00, translating into sizeable upside from the stock's current price. Adaptimmune designs, develops, manufactures, and delivers innovative cell therapies via the company's unique T-cell receptor (TCR) platform to treat cancers across multiple solid tumor types.
Read more